A JAK inhibitor that treats inflammatory diseases such as rheumatoid arthritis, psoriasis, and atopic dermatitis by inhibiting an enzyme called Janus Kinase. There is evidence that it increases the risk of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE), but no studies have comprehensively examined the risk of skin diseases. A research team from … Continue reading JAK Inhibitors and the Risk of Cardiovascular Events in Skin Disease Patients: A Meta-Analysis